Tempus Ai, Inc.
A maker of AI-driven precision medicine tools, Tempus runs a platform that analyzes tumor samples and other health data to help doctors personalize cancer, hereditary, and neuropsychiatry care. Its Diagnostics line performs genomic tests, while Data & Applications sells anonymized health insights and trial-matching services to drugmakers. Founded in 2015 by Eric Lefkofsky, it takes its name from the Latin for "time" — a nod to giving patients more of it.
Sold 771.1K
Granted 10.0K · Sold 27.8K
Granted 5.9K
Granted 10.0K · Sold 8.7K
Granted 5.9K
Granted 10.0K · Sold 33.8K
Granted 13.6K · Sold 4.3K
Granted 24.0K · Sold 4.1K
Granted 5.9K
Granted 5.9K
Granted 5.9K
Granted 5.9K · Sold 500
Granted 5.9K
Granted 5.9K · Sold 2.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lefkofsky Eric PCEO and Chairman, Director, 10% owner · 47 transactions | — | 46.86M | — | — | 771.1K |
| Fukushima RyanCEO, Data · 5 transactions | -33.6% | 609.9K | 10.0K | — | 27.8K |
| Leonsis TheodoreDirector · 1 transaction | +4.5% | 137.8K | 5.9K | — | — |
| Polovin AndrewEVP, Chief Legal Officer · 2 transactions | -7% | 128.2K | 10.0K | — | 8.7K |
| Barris Peter JDirector · 1 transaction | +5.1% | 121.4K | 5.9K | — | — |
| Rogers James WilliamChief Financial Officer · 4 transactions | -17.2% | 114.9K | 10.0K | — | 33.8K |
| Schoenherr Thomas EdwardCEO, Diagnostics · 3 transactions | -8.4% | 87.0K | 13.6K | — | 4.3K |
| Bartolucci Ryan MChief Accounting Officer · 2 transactions | +36.7% | 74.0K | 24.0K | — | 4.1K |
| Gottlieb ScottDirector · 1 transaction | +17% | 40.7K | 5.9K | — | — |
| West NadjaDirector · 1 transaction | +18.4% | 38.0K | 5.9K | — | — |
| Belcher Eric DDirector · 1 transaction | +20% | 35.5K | 5.9K | — | — |
| Epstein David RDirector · 3 transactions | +20.8% | 31.5K | 5.9K | — | 500 |
| Frederick Wayne A.I.Director · 1 transaction | +23.8% | 30.7K | 5.9K | — | — |
| Doudna Jennifer ADirector · 2 transactions | +14.3% | 25.9K | 5.9K | — | 2.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -853.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.